NCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
Clinical Trials
7 trialsNCT05572645 2024-02-26
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Fudan University
Completed
NCT04367090 2023-09-18
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05252546 2022-12-23
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03735966 2022-12-01
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
Henan Cancer Hospital
Phase 2 Completed
NCT04756921 2021-02-16
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Fudan University
Completed
NCT01937689 2018-07-09
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed